We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Collaboration to Develop Diagnostic Tests for Breast Cancer

By HospiMedica staff writers
Posted on 26 Mar 2004
A research collaboration for the discovery and development of in vitro diagnostic tests for the early detection of breast cancer has been announced by Abbott Laboratories (Abbott Park, IL, USA) and Europroteome AG (Henningsdorf, Germany). More...


The collaboration will seek to identify novel markers for breast cancer diagnosis and potential screening and to develop tests for use on Abbott's automated instrument systems. Under the agreement, Europroteome will apply advanced proteomic and bioinformatic technologies to analyze serum samples from women with breast
cancer. Data will be aligned with a panel of cancer markers from Abbott. Combinations of markers will be selected for further development and integration into Abbott's instrument platforms, used widely in hospitals and clinical laboratories throughout the world.

Abbott will make upfront and milestone payments to Europroteome and
provide commercial assays and instruments. Abbott will have an option for a royalty-bearing license to the results from the research collaboration and will be responsible for commercial assay development and worldwide sales and marketing.

"We believe this collaboration will further enhance our ability to
develop important diagnostic tools for the early detection of breast cancer, which is key to successful treatment intervention,” said Edward L. Michael, president, Abbott Molecular Diagnostics. "We are impressed by Europroteome's approach to integrate diagnostic industry platform requirements into the discovery strategy.”


Europroteome is a product-focused biopharmaceutical company with an
associated network of oncology experts. The firm operates a state-of-the-art proteomics and gene-expression laboratory in Berlin-Hennigsdorf, Germany. Europroteome's mission is to advance the development of cancer drugs and diagnostics based on a unique discovery and validation process that merges both molecular and clinical data. Europroteome founded and operates the Clinical Cancer Network (CCN), which is one of the largest, best-organized and most interactive networks of its kind. The CCN currently consists of
experts from about 20 European institutions and is a unique source of medical and scientific know-how.




Related Links:
Abbott
Europroteome

Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hypodermic Syringe
SurTract™ Safety Syringe
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.